Collegium Pharmaceutical
Yahoo Finance • 10 months ago
13 Best Short Squeeze Stocks To Buy Now
In this piece, we will take a look at the 13 best short squeeze stocks to buy now. If you want to skip our primer on short squeezing, and some of the greatest short squeezes in history, then you can take a look at the 5 Best Short Squeeze... Full story
Yahoo Finance • last year
Collegium Pharmaceutical (NASDAQ:COLL) ascends 8.3% this week, taking five-year gains to 77%
The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up more than the market average. But Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has fallen short of that second goal, with... Full story
Yahoo Finance • last year
Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld... Full story
Yahoo Finance • last year
12 Cheap NASDAQ Stocks To Buy
In this piece, we will take a look at the 12 cheap NASDAQ stocks to buy. To skip our overview of one of the world's largest stock exchanges and some recent financial news, read 5 Cheap NASDAQ Stocks To Buy. Stocks markets have been taking... Full story
Yahoo Finance • last year
Collegium Announces $25 Million Accelerated Share Repurchase Program
STOUGHTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,... Full story
Yahoo Finance • last year
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,... Full story
Yahoo Finance • last year
Collegium Reports Third Quarter 2023 Financial Results
– Q3’23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3’23 GAAP Net Income of $20.6 Million vs. Q3’22 GAAP Net Income of $0.5 Million – – Record Q3’23 Adjusted EBITDA of $89.4 Million, Up 19% Year-over-Year – – Received Exten... Full story
Yahoo Finance • last year
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,... Full story
Yahoo Finance • last year
Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,... Full story
Yahoo Finance • last year
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
STOUGHTON, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,... Full story
Yahoo Finance • 2 years ago
Collegium Reports First Quarter 2023 Financial Results
– Generated Record Net Revenue of $144.8 Million – – Delivered Record Belbuca® and Xtampza® ER Net Revenue – – Ended Q1’23 with Cash Balance of $269.5 Million – – Reaffirmed Full Year 2023 Guidance – – Conference Call Scheduled for Tod... Full story
Yahoo Finance • 2 years ago
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions... Full story
Yahoo Finance • 2 years ago
Collegium to Participate in 22nd Annual Needham Virtual Healthcare Conference
STOUGHTON, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions... Full story
Yahoo Finance • 2 years ago
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results
– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million – – Ended 2022 with Cash Balance of $173.7 Million – – Reaffirmed 2023 Financial Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STO... Full story
Yahoo Finance • 2 years ago
Collegium Publishes Inaugural 2022 Environmental, Social and Governance Report
STOUGHTON, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced the release of its inaugural Environmental, Social and Governance... Full story
Yahoo Finance • 2 years ago
Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering
STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “no... Full story
Yahoo Finance • 2 years ago
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible seni... Full story
Yahoo Finance • 2 years ago
Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results
-Results at or above high-end of 2022 earnings guidance- -Final fourth quarter and full year 2022 financial results to be announced after market closes on Thursday, February 23- STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Colle... Full story
Yahoo Finance • 2 years ago
Collegium Provides 2023 Financial Guidance
– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million – – Adjusted Operating Expenses* Expected in the Range of $135.0 Million to $145.0 Million – – Adjusted EBITDA* Expected in the Range of $355.0 Million to... Full story
Yahoo Finance • 2 years ago
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors
Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Brings 30 years of experience building private and public development-stage and commercial biopharmaceutical companies and has overseen severalsuccessful IPOs and trade... Full story
